AngioDynamics Company Profile (NASDAQ:ANGO)

About AngioDynamics (NASDAQ:ANGO)

AngioDynamics logoAngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ANGO
  • CUSIP: 03475V10
  • Web:
  • Market Cap: $577.45 million
  • Outstanding Shares: 36,780,000
Average Prices:
  • 50 Day Moving Avg: $15.66
  • 200 Day Moving Avg: $16.46
  • 52 Week Range: $11.85 - $18.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.09
  • P/E Growth: 1.51
Sales & Book Value:
  • Annual Revenue: $356.15 million
  • Price / Sales: 1.62
  • Book Value: $14.46 per share
  • Price / Book: 1.09
  • EBIDTA: $49.13 million
  • Net Margins: -7.91%
  • Return on Equity: 4.87%
  • Return on Assets: 3.49%
  • Debt-to-Equity Ratio: 0.21%
  • Current Ratio: 2.91%
  • Quick Ratio: 1.80%
  • Average Volume: 288,744 shs.
  • Beta: 1.02
  • Short Ratio: 9.21

Frequently Asked Questions for AngioDynamics (NASDAQ:ANGO)

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Thursday, March, 30th. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.15 by $0.04. The company earned $85.60 million during the quarter, compared to analyst estimates of $88.29 million. AngioDynamics had a positive return on equity of 4.87% and a negative net margin of 7.91%. The firm's revenue was down 2.1% on a year-over-year basis. During the same quarter last year, the business posted $0.15 earnings per share. View AngioDynamics' Earnings History.

When will AngioDynamics make its next earnings announcement?

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 11th 2017. View Earnings Estimates for AngioDynamics.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics updated its FY17 earnings guidance on Thursday, March, 30th. The company provided EPS guidance of $0.68-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.67. The company issued revenue guidance of $352-355 million, compared to the consensus revenue estimate of $358.66 million.

Where is AngioDynamics' stock going? Where will AngioDynamics' stock price be in 2017?

5 brokers have issued 12 month price targets for AngioDynamics' shares. Their predictions range from $17.00 to $21.00. On average, they expect AngioDynamics' stock price to reach $18.70 in the next year. View Analyst Ratings for AngioDynamics.

What are analysts saying about AngioDynamics stock?

Here are some recent quotes from research analysts about AngioDynamics stock:

  • 1. According to Zacks Investment Research, "Over the last three months, AngioDynamics has outperformed the broader industry in terms of price.  Meanwhile, the company reported a mixed third quarter of fiscal 2017, wherein adjusted earnings surpassed the Zacks Consensus Estimate while revenues missed the same. The company has also provided positive earnings guidance for fiscal 2017. Notably, the major growth drivers for the company are the Perpheral Vascular, the NanoKnife and BioFlo Midline product lines. Meanwhile, the discontinuity of the Celerity tip location program under its vascular segment might dent operational efficiency over the long haul. A sluggish capital spending environment is adversely affecting AngioDynamics’ top-line growth. AngioDynamics is exposed to a stringent regulatory environment. Regulatory setbacks might dampen approvals for pipeline products, which will in turn hurt overall growth." (4/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)
  • 3. KeyCorp analysts commented, "The initiation of the PIII for ONS-3010 in psoriasis has been delayed slightly to 2016 from 3Q16. The PIII design has been agreed to by FDA and EMA and the interchangeability study design has been discussed with the FDA. The company continues to seek partnerships in the interim to fund its pipeline programs. ONS-3010 Development Stalling: Mgmt plans to initiate the PIII interchangeability trial with first patient enrolled by end of this month/early October w/ initial patient enrollment in EU/Canada and with patient enrollment in U.S. expected to start in early Jan 2017. We note that mgmt stated the FDA and EMA signed off on a PIII trial design and the company basically needs to submit an IND detailing the pre-agreed plan." (9/12/2016)

Who are some of AngioDynamics' key competitors?

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the folowing people:

  • Howard W. Donnelly, Independent Chairman of the Board
  • James C. Clemmer, President, Chief Executive Officer, Director
  • Michael Greiner, Chief Financial Officer, Executive Vice President
  • Gary Barrett, Senior Vice President,Quality and Regulatory Affairs
  • Ben Davis, Senior Vice President, Business Development
  • Barbara Kucharczyk, Senior Vice President-Global Operations
  • Stephen A. Trowbridge, Senior Vice President, General Counsel
  • Eileen O'Shea Auen, Director
  • Jan Stern Reed, Director
  • David F. Burgstahler, Independent Director

Who owns AngioDynamics stock?

AngioDynamics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.00%), AVISTA CAPITAL PARTNERS GP, LLC (6.30%), Vanguard Group Inc. (0.00%), Broadfin Capital LLC (3.98%), FMR LLC (0.00%) and Royce & Associates LP (0.00%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler and Stephen A Trowbridge. View Institutional Ownership Trends for AngioDynamics.

Who sold AngioDynamics stock? Who is selling AngioDynamics stock?

AngioDynamics' stock was sold by a variety of institutional investors in the last quarter, including RGM Capital LLC, Systematic Financial Management LP, Alliancebernstein L.P., FMR LLC, Bogle Investment Management L P DE, Acadian Asset Management LLC, Renaissance Technologies LLC and JPMorgan Chase & Co.. Company insiders that have sold AngioDynamics stock in the last year include Avista Capital Partners Gp, Ll and David F Burgstahler. View Insider Buying and Selling for AngioDynamics.

Who bought AngioDynamics stock? Who is buying AngioDynamics stock?

AngioDynamics' stock was bought by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc., Bank of America Corp DE, Royce & Associates LP, American Century Companies Inc., Vanguard Group Inc., Ameriprise Financial Inc., Schwab Charles Investment Management Inc. and Capital One National Association. View Insider Buying and Selling for AngioDynamics.

How do I buy AngioDynamics stock?

Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AngioDynamics' stock price today?

One share of AngioDynamics stock can currently be purchased for approximately $15.70.

MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
Community Ranking:  1.8 out of 5 ()
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AngioDynamics (NASDAQ:ANGO) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $18.70 (19.11% upside)

Analysts' Ratings History for AngioDynamics (NASDAQ:ANGO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017Cantor FitzgeraldSet Price TargetOverweight -> Overweight$20.00 -> $21.00HighView Rating Details
4/1/2017Craig HallumSet Price TargetBuy$20.00LowView Rating Details
3/30/2017Canaccord GenuityReiterated RatingHold$17.50MediumView Rating Details
2/8/2017Barclays PLCInitiated CoverageEqual Weight$17.00N/AView Rating Details
9/12/2016KeyCorpSet Price TargetBuy$18.00N/AView Rating Details
4/8/2016Piper Jaffray CompaniesInitiated CoverageNeutral$12.00N/AView Rating Details
11/10/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
9/23/2015SidotiInitiated CoverageNeutral$14.50N/AView Rating Details
(Data available from 5/30/2015 forward)


Earnings History for AngioDynamics (NASDAQ:ANGO)
Earnings by Quarter for AngioDynamics (NASDAQ:ANGO)
Earnings History by Quarter for AngioDynamics (NASDAQ ANGO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2017Q3 2017$0.15$0.19$88.29 million$85.60 millionViewN/AView Earnings Details
1/6/2017Q217$0.16$0.19$91.09 million$89.00 millionViewListenView Earnings Details
10/5/2016Q117$0.13$0.17$86.09 million$88.10 millionViewN/AView Earnings Details
7/13/2016Q416$0.16$0.19$88.64 million$93.40 millionViewListenView Earnings Details
4/7/2016Q3$0.14$0.15$85.43 million$87.40 millionViewListenView Earnings Details
1/7/2016Q216$0.14$0.14$88.67 million$89.20 millionViewN/AView Earnings Details
10/8/2015Q116$0.11$0.11$84.70 million$83.70 millionViewN/AView Earnings Details
7/16/2015Q415$0.14$0.14$91.67 million$90.90 millionViewListenView Earnings Details
4/9/2015Q315$0.15$0.12$88.69 million$86.60 millionViewN/AView Earnings Details
1/8/2015Q215$0.15$0.17$90.90 million$92.10 millionViewN/AView Earnings Details
10/9/2014Q115$0.11$0.16$85.35 million$87.30 millionViewListenView Earnings Details
7/23/2014Q414$0.12$0.18$93.65 million$94.07 millionViewListenView Earnings Details
4/9/2014Q314$0.09$0.16$86.85 million$88.20 millionViewListenView Earnings Details
1/9/2014Q2$0.07$0.14$87.54 million$88.60 millionViewListenView Earnings Details
10/10/2013Q114$0.03$0.04$82.54 million$83.60 millionViewN/AView Earnings Details
7/11/2013Q4 2013$0.06$0.07$86.43 million$90.00 millionViewN/AView Earnings Details
4/8/2013Q3 2013$0.05$0.08$81.70 million$81.60 millionViewN/AView Earnings Details
1/3/2013Q2 2013$0.09$0.10$87.40 million$87.00 millionViewN/AView Earnings Details
10/8/2012Q113$0.09$0.10$84.35 million$83.40 millionViewN/AView Earnings Details
7/12/2012$0.08$0.09ViewN/AView Earnings Details
4/4/2012$0.07$0.09ViewN/AView Earnings Details
1/5/2012$0.12$0.13ViewN/AView Earnings Details
10/6/2011$0.09$0.08ViewN/AView Earnings Details
7/14/2011$0.10$0.11ViewN/AView Earnings Details
4/5/2011$0.12$0.15ViewN/AView Earnings Details
1/4/2011$0.12$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AngioDynamics (NASDAQ:ANGO)
2017 EPS Consensus Estimate: $0.61
2018 EPS Consensus Estimate: $0.78
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.13$0.13$0.13
Q2 20171$0.17$0.17$0.17
Q3 20172$0.15$0.16$0.16
Q4 20172$0.14$0.16$0.15
Q1 20181$0.18$0.18$0.18
Q2 20181$0.15$0.15$0.15
Q3 20181$0.23$0.23$0.23
Q4 20181$0.22$0.22$0.22
(Data provided by Zacks Investment Research)


Dividend History for AngioDynamics (NASDAQ:ANGO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for AngioDynamics (NASDAQ:ANGO)
Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 79.52%
Insider Trades by Quarter for AngioDynamics (NASDAQ:ANGO)
Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)
Insider Trades by Quarter for AngioDynamics (NASDAQ:ANGO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/12/2017Avista Capital Partners Gp, LlMajor ShareholderSell2,350,000$16.00$37,600,000.00View SEC Filing  
8/5/2016Avista Capital Partners Gp, LlMajor ShareholderSell2,241,000$14.62$32,763,420.00View SEC Filing  
8/5/2016David F BurgstahlerDirectorSell2,250,000$14.62$32,895,000.00View SEC Filing  
5/6/2016Charles R GreinerVPSell3,508$12.31$43,183.48View SEC Filing  
4/25/2016Stephen A TrowbridgeSVPSell12,940$12.30$159,162.00View SEC Filing  
4/14/2014Matthew KapustaSVPBuy1,000$13.90$13,900.00View SEC Filing  
10/18/2013Vincent BucciDirectorBuy5,000$15.20$76,000.00View SEC Filing  
10/17/2013Howard W DonnellyDirectorSell20,000$15.06$301,200.00View SEC Filing  
7/22/2013Kevin J GouldDirectorBuy2,700$12.00$32,400.00View SEC Filing  
5/9/2013Charles R GreinerVPSell1,495$10.38$15,518.10View SEC Filing  
3/12/2013Vincent BucciDirectorBuy85,000$10.77$915,450.00View SEC Filing  
2/14/2013Vincent BucciDirectorBuy2,000$12.17$24,340.00View SEC Filing  
1/11/2013Kevin J GouldDirectorBuy2,700$11.58$31,266.00View SEC Filing  
11/5/2012Jeffrey GoldDirectorBuy1,000$10.56$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AngioDynamics (NASDAQ:ANGO)
Latest Headlines for AngioDynamics (NASDAQ:ANGO)
DateHeadline logoAngioDynamics, Inc. (ANGO) Given Consensus Recommendation of "Buy" by Analysts - May 29 at 4:56 PM logoAnalysts Set AngioDynamics, Inc. (ANGO) Price Target at $18.70 - May 5 at 11:44 PM logoAngioDynamics, Inc. (ANGO) Given Consensus Rating of "Buy" by Analysts - May 2 at 6:22 PM logoAngioDynamics (ANGO) Earns Media Sentiment Score of 0.10 - May 2 at 2:20 PM logoAngioDynamics (ANGO) Down 11.7% Since Earnings Report: Can It Rebound? - May 1 at 9:33 AM logoAngioDynamics, Inc. (ANGO) Expected to Post Quarterly Sales of $90.76 Million - April 29 at 8:17 AM logoAngioDynamics, Inc. (ANGO) Expected to Post Earnings of $0.16 Per Share - April 27 at 9:16 PM logoFavorable Press Coverage Very Likely to Affect AngioDynamics (ANGO) Share Price - April 27 at 2:40 PM logoSomewhat Positive Press Coverage Very Likely to Impact AngioDynamics (ANGO) Stock Price - April 24 at 5:14 PM logoAngioDynamics (ANGO) Receiving Somewhat Positive Press Coverage, Report Finds - April 20 at 2:36 PM logoAdvaxis Appoints Anthony Lombardo as Chief Business Officer - April 19 at 8:58 AM logoShort Interest in AngioDynamics, Inc. (ANGO) Rises By 3.9% - April 18 at 9:35 AM logoPositive News Coverage Somewhat Likely to Impact AngioDynamics (ANGO) Stock Price - April 17 at 12:01 PM logoAngioDynamics, Inc. (ANGO) Major Shareholder Sells $37,600,000.00 in Stock - April 14 at 7:41 PM logoAngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : April 10, 2017 - April 10 at 8:33 PM logoZacks Investment Research Lowers AngioDynamics, Inc. (ANGO) to Hold - April 10 at 4:33 PM logoAnalysts Set Expectations for AngioDynamics, Inc.'s FY2019 Earnings (ANGO) - April 10 at 12:40 PM logoAngioDynamics, Inc. (ANGO) Given a $21.00 Price Target at Cantor Fitzgerald - April 8 at 12:02 AM logoAngioDynamics prices stock offering at $16.20 - April 7 at 7:53 AM logoAngioDynamics, Inc. :ANGO-US: Earnings Analysis: Q3, 2017 By the Numbers : April 4, 2017 - April 7 at 5:51 AM logo5 Cheap Value Stocks to Tame a Capricious Market in Q2 - April 7 at 5:51 AM logoETFs with exposure to AngioDynamics, Inc. : April 5, 2017 - April 7 at 5:51 AM logoAngioDynamics Announces Secondary Offering of 2.35 Million Shares of Common Stock by Selling Stockholders - April 7 at 5:50 AM logoAngioDynamics Announces Pricing of Secondary Offering by Selling Stockholders - April 7 at 5:50 AM logo Brokerages Anticipate AngioDynamics, Inc. (ANGO) to Announce $0.15 Earnings Per Share - April 6 at 5:37 PM logoAngioDynamics, Inc. (ANGO) Given Consensus Recommendation of "Buy" by Brokerages - April 5 at 3:39 PM logoAngioDynamics, Inc. (ANGO) Earns Buy Rating from Cantor Fitzgerald - April 5 at 9:01 AM logoAngioDynamics, Inc. (ANGO) Receives Hold Rating from Canaccord Genuity - April 5 at 9:01 AM logoANGIODYNAMICS INC Files SEC form 10-Q, Quarterly Report - April 3 at 3:52 PM logoFY2017 EPS Estimates for AngioDynamics, Inc. Lifted by Analyst (ANGO) - April 3 at 10:07 AM logoAngioDynamics, Inc. (ANGO) Given a $20.00 Price Target by Craig Hallum Analysts - April 3 at 12:46 AM logoAngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View - March 31 at 3:41 PM logoQ3 2017 AngioDynamics Inc Earnings Release - Before Market Open - March 30 at 9:00 PM logoAngioDynamics downgraded by KeyBanc Capital Mkts - March 30 at 9:00 PM logoEdited Transcript of ANGO earnings conference call or presentation 30-Mar-17 12:00pm GMT - March 30 at 9:00 PM logoAngioDynamics' (ANGO) Hold Rating Reiterated at Canaccord Genuity - March 30 at 4:31 PM logoAngioDynamics, Inc. (ANGO) Given "Buy" Rating at Cantor Fitzgerald - March 30 at 4:31 PM logoAngioDynamics Reports Fiscal 2017 Third Quarter Results - March 30 at 3:57 PM logoAngioDynamics tops 3Q profit forecasts - March 30 at 3:57 PM logoAngioDynamics, Inc. (ANGO) Releases Earnings Results, Beats Expectations By $0.04 EPS - March 30 at 9:49 AM logoAngioDynamics, Inc. (ANGO) Issues FY17 Earnings Guidance - March 30 at 9:01 AM logoAngioDynamics beats by $0.04, misses on revenue - March 30 at 6:31 AM logoAngioDynamics, Inc. (ANGO) Stock Rating Upgraded by Zacks Investment Research - March 29 at 12:58 PM logoHere's Why You Should Steer Clear of Mednax (MD) for Now - March 29 at 11:30 AM logoAngioDynamics, Inc. (ANGO) Set to Announce Quarterly Earnings on Thursday - March 29 at 7:08 AM logoAngioDynamics To Host Investor Day on Thursday, April 6, 2017, in New York City - March 27 at 7:43 AM logoAngioDynamics to Report Fiscal 2017 Third Quarter Financial Results - March 20 at 7:02 AM logoAngioDynamics Microwave Tissue Ablation System Now CE Marked - March 15 at 3:43 PM logoAngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System - March 14 at 3:28 PM logo6:01 am AngioDynamics receives CE Mark certification for the Solero Microwave Tissue Ablation System - March 14 at 3:28 PM



AngioDynamics (ANGO) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by Staff